Renovaro Regains Compliance With NASDAQ Listing Requirement
Renovaro Regains Compliance With NASDAQ Listing Requirement
Renovaro重新符合納斯達克上市要求
Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule, 5550(a)(2). The Company's security will continue to be listed and traded on The Nasdaq Stock Market and this matter is now closed.
Renovaro Inc.(納斯達克:RENB)是一家由人工智能驅動的癌症診斷和治療的先驅,今天宣佈收到納斯達克證券市場有限責任公司("納斯達克")上市資格部的通知,告知公司已恢復符合納斯達克上市規則5550(a)(2)下的最低買盤價格要求。公司的安防將繼續在納斯達克證券市場上市和交易,此事現已結束。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。